全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

30 Years on Selected Issues in the Prevention of HIV among Persons Who Inject Drugs

DOI: 10.1155/2013/346372

Full-Text   Cite this paper   Add to My Lib

Abstract:

After 30 years of extensive research on human immunodeficiency virus (HIV) among persons who inject drugs (PWID), we now have a good understanding of the critical issues involved. Following the discovery of HIV in 1981, epidemics among PWID were noted in many countries, and consensus recommendations for interventions for reducing injection related HIV transmission have been developed. While high-income countries have continued to develop and implement new Harm Reduction programs, most low-/middle-income countries have implemented Harm Reduction at very low levels. Modeling of combined prevention programming including needle exchange (NSP) and antiretroviral therapy (ARV) suggests that NSP be given the highest priority. Future HIV prevention programming should continue to provide Harm Reduction programs for PWID coupled with interventions aimed at reducing sexual transmission. As HIV continues to spread in low- and middle-income countries, it is important to achieve and maintain high coverage of Harm Reduction programs in these locations. As PWID almost always experience multiple health problems, it will be important to address these multiple problems within a comprehensive approach grounded in a human rights perspective. 1. Introduction We now have three decades of experience in HIV prevention for persons who inject drugs (PWID); a vast amount of data has been collected, and much is known. In this paper we will briefly review what has been learned in these three decades and discuss what we believe are several critical issues for future research and public health practice with respect to HIV and injecting drug use. We will not, however, undertake a systematic review of the epidemiology of HIV infection among PWID nor a review of the implementation of various interventions to prevent HIV infection among PWID. For those topics, we would refer readers to the Lancet series [1] and the most recent UNAIDS Annual Report [2]. (Though we would note much of this epidemiological and service provision information needs to be updated.) We will also not examine in depth the current international economics of HIV prevention for PWID. We would note that due to the international economic recession, there is declining international support for HIV prevention for PWID. The global fund for AIDS, tuberculosis, and malaria has had considerable difficulties in raising monies from high-income countries [3, 4], and the US President’s Emergency Program for AIDS Relief (PEPFAR), the largest single donor program, is now moving towards a “country ownership” stage, in which the

References

[1]  B. M. Mathers, L. Degenhardt, B. Phillips et al., “Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review,” The Lancet, vol. 372, no. 9651, pp. 1733–1745, 2008.
[2]  UNAIDS, UNAIDS Report on the Global AIDS Epidemic, edited by HIV/AIDS JUNPo, UNAIDS, 2012.
[3]  B. Conway, J. Prasad, R. Reynolds et al., “Directly observed therapy for the management of HIV-infected patients in a methadone program,” Clinical Infectious Diseases, vol. 38, supplement 5, pp. S402–S408, 2004.
[4]  D. McNeil, “Global fund sees changes, not all of them welcomed,” in New York Times, New York Times, New York, NY, USA, 2012.
[5]  CDC CfDC, “First report of AIDS,” in MMWR Weekly Report, vol. 50, Centers for Disease Control, Atlanta, GA, USA, 1981.
[6]  S. D. Holmberg, “The estimated prevalence and incidence of HIV in 96 large US metropolitan areas,” American Journal of Public Health, vol. 86, no. 5, pp. 642–654, 1996.
[7]  R. Robertson and A. Richardson, “Heroin injecting and the introduction of HIV/AIDS into a Scottish city,” Journal of the Royal Society of Medicine, vol. 100, no. 11, pp. 491–494, 2007.
[8]  H. J. A. van Haastrecht, J. A. R. van den Hoek, C. Bardoux, A. Leentvaar-Kuypers, and R. A. Coutinho, “The course of the HIV epidemic among intravenous drug users in Amsterdam, The Netherlands,” American Journal of Public Health, vol. 81, no. 1, pp. 59–62, 1991.
[9]  C. van den Berg, C. Smit, G. van Brussel, R. Coutinho, and M. Prins, “Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users,” Addiction, vol. 102, no. 9, pp. 1454–1462, 2007.
[10]  G. V. Stimson, “AIDS and injecting drug use in the United Kingdom, 1987–1993: the policy response and the prevention of the epidemic,” Social Science and Medicine, vol. 41, no. 5, pp. 699–716, 1995.
[11]  A. Wodak and L. Maher, “The effectiveness of harm reduction in preventing HIV among injecting drug users,” New South Wales public health bulletin, vol. 21, no. 3-4, pp. 69–73, 2010.
[12]  D. F. Musto, “America's first cocaine epidemic,” The Wilson Quarterly, vol. 13, no. 3, 1989.
[13]  W. Anderson, “The New York needle trial: the politics of public health in the age of AIDS,” American Journal of Public Health, vol. 81, no. 11, pp. 1506–1517, 1991.
[14]  WHO UNODC and UNAIDS, WHO, UNODC, UNAIDS Technical Guide For Countries to Set Targets For Universal Access To HIV Prevention, Treamtent, and Care of Injection Drug Users, WHO, Geneva, Switzerland, 2009.
[15]  C. Aceijas, G. V. Stimson, M. Hickman, and T. Rhodes, “Global overview of injecting drug use and HIV infection among injecting drug users,” AIDS, vol. 18, no. 17, pp. 2295–2303, 2004.
[16]  D. C. Des Jarlais, J. P. Feelemyer, S. N. Modi et al., “Transitions from injection-drug-use-concentrated to self-sustaining heterosexual HIV epidemics: patterns in the international data,” Plos One, vol. 7, no. 3, article e31227, 2012.
[17]  D. C. Des Jarlais, H. Hagan, S. R. Friedman et al., “Maintaining low HIV seroprevalence in populations of injecting drug users,” Journal of the American Medical Association, vol. 274, no. 15, pp. 1226–1231, 1995.
[18]  J. T. L. Iverson, H. Wand, J. Kaldor, and L. Maher, “Low Incidence of HIV among people who inject drugs over two decades in Australia,” in Proceedings of the International AIDS Conference, AIDS, Washington, DC, USA, July 2012.
[19]  S. A. Strathdee, D. M. Patrick, S. L. Currie et al., “Needle exchange is not enough: lessons from the Vancouver injecting drug use study,” AIDS, vol. 11, no. 8, pp. F59–F65, 1997.
[20]  D. Paraskevis, G. Nikolopoulos, C. Tsiara et al., “HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report,” Eurosurveillance, vol. 16, no. 36, article 1, 2011.
[21]  EMCDDA/ECDC, HIV in Injecting Drug Users in the EU/EEA, Following a Reported increase in Cases in Greece and Romania, Joint Publications, EMCDDA, Lisbon, Portugal, 2012.
[22]  A. . Fotiou, K. Micha, D. Paraskevis, M. Terzidou, M. Malliori, and A. Hatzakis, HIV Outbreak Among Injecting Drug Users in Greece, EMCDDA, Athens, Greece, 2012.
[23]  A. S. de Vos, J. J. van der Helm, M. Prins, and M. E. E. Kretzschmar, “Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam: evidence for harm reduction?” in Proceedings of the International AIDS Conference, Washington DC, USA, July 2012.
[24]  EMCDDA, Health and Social Responses (HSR) 2009 Statistical Bulletin, Statistical Bulletins, EMCDDA, Lisbon, Portugal, 2009.
[25]  D. C. Des Jarlais, K. Arasteh, C. McKnight et al., “HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors,” Drug and Alcohol Dependence, vol. 109, no. 1–3, pp. 154–160, 2010.
[26]  A. M. Rodes, M. Suarez, C. Menoyo, L. de la Fuente, A. Bolea, and F. Parras, “Implementation of comprehensive harm reduction interventions in Spain. 1993–2000,” in Proceedings of the XIV International AIDS Conference (IAC '12), pp. 22–27, Barcelona, Spain, July 2012.
[27]  J. Montaner, V. D. Lim, B. Yip et al., “Expanded HAART coverage is associated with decreased HIV/AIDS morbidity and HIV new diagnoses: an update on the 'treatment as prevention' experience in British Columbia, Canada,” in Proceedings of the International AIDS Conference, Washington, DC, USA, 2012.
[28]  B. M. Mathers, L. Degenhardt, H. Ali et al., “HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage,” The Lancet, vol. 375, no. 9719, pp. 1014–1028, 2010.
[29]  J. Cohen, “No opiate substitutes for the masses of IDUs,” Science, vol. 329, no. 5988, pp. 165–167, 2010.
[30]  T. Rhodes, L. Mikhailova, A. Sarang et al., “Situational factors influencing drug injecting, risk reduction and syringe exchange in Togliatti City, Russian Federation: a qualitative study of micro risk environment,” Social Science and Medicine, vol. 57, no. 1, pp. 39–54, 2003.
[31]  R. E. Booth, J. Kennedy, T. Brewster, and O. Semerik, “Drug injectors and dealers in Odessa, Ukraine,” Journal of Psychoactive Drugs, vol. 35, no. 4, pp. 419–426, 2003.
[32]  D. Wolfe, M. P. Carrieri, and D. Shepard, “Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward,” The Lancet, vol. 376, no. 9738, pp. 355–366, 2010.
[33]  T. Burki, “Russia's drug policy fuels infectious disease epidemics,” The Lancet Infectious Diseases, vol. 12, no. 4, pp. 275–276, 2012.
[34]  D. Wolfe, “Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union,” International Journal of Drug Policy, vol. 18, no. 4, pp. 246–254, 2007.
[35]  A. Uusküla, M. Kals, K. Denks et al., “The prevalence of chlamydial infection in Estonia: a population-based survey,” International Journal of STD and AIDS, vol. 19, no. 7, pp. 455–458, 2008.
[36]  A. Uusküla, L. A. McNutt, J. Dehovitz, K. Fischer, and R. Heimer, “High prevalence of blood-borne virus infections and high-risk behaviour among injecting drug users in Tallinn, Estonia,” International Journal of STD and AIDS, vol. 18, no. 1, pp. 41–46, 2007.
[37]  S. D. Pinkerton, “How many HIV infections are prevented by Vancouver Canada's supervised injection facility?” International Journal of Drug Policy, vol. 22, no. 3, pp. 179–183, 2011.
[38]  E. H. Kaplan, “Needles that kill: modeling human immunodeficiency virus transmission via shared drug injection equipment in shooting galleries,” Reviews of Infectious Diseases, vol. 11, no. 2, pp. 289–298, 1989.
[39]  S. A. Strathdee, T. B. Hallett, N. Bobrova et al., “HIV and risk environment for injecting drug users: the past, present, and future,” The Lancet, vol. 376, no. 9737, pp. 268–284, 2010.
[40]  H. Raymond, HIV Prevention Funding: Transmission Problems, 2012.
[41]  J. Blanchard, Summary of Interim Results From the Winnipeg Injection Drug Epidemiology (WIDE) Study, Manitoba Health, Manitoba, Canada, 1998.
[42]  S. A. Strathdee, D. M. Patrick, C. P. Archibald et al., “Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada,” Addiction, vol. 92, no. 10, pp. 1339–1347, 1997.
[43]  Centers for Disease Control and Prevention, Overview of the Cost Effectiveness of HIV Treatment, CDC HIV/AIDS Prevention Programs, Centers for Disease Control and Prevention, Atlanta, GA, USA, 2012.
[44]  S. Mostardt, N. Hanhoff, J. Wasem et al., “Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNA K3A Study,” The European Journal of Health Economics. In press.
[45]  NASEN, North American Syringe Exchange Network (NASEN), 2011.
[46]  EMCDDA, “vention and control of infectious diseases among people who inject drugs,” edited by EMCDDA, European Centre for Disease Prevention and Control, Stockholm, Sweden, 2011.
[47]  J. O. Merrill, “Integrating medical care and addiction treatment,” Journal of General Internal Medicine, vol. 18, no. 1, pp. 68–69, 2003.
[48]  J. J. Benshoff, L. K. Harrawood, and D. S. Koch, “Substance abuse and the elderly: unique issues and concerns,” Journal of Rehabilitation, vol. 69, no. 2, pp. 43–48, 2003.
[49]  J. A. Mitty, V. E. Stone, M. Sands, G. Macalino, and T. Flanigan, “Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress,” Clinical Infectious Diseases, vol. 34, no. 7, pp. 984–990, 2002.
[50]  G. M. Lucas, P. J. Weidle, S. Hader, and R. D. Moore, “Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study,” Clinical Infectious Diseases, vol. 38, supplement 5, pp. S409–S413, 2004.
[51]  H. Hagan, “Agent, host, and environment: hepatitis C virus in people who inject drugs,” Journal of Infectious Diseases, vol. 204, no. 12, pp. 1819–1821, 2011.
[52]  H. Hagan, E. R. Pouget, D. C. Des Jarlais, and C. Lelutiu-Weinberger, “Meta-regression of hepatitis c virus infection in relation to time since onset of illicit drug injection: the influence of time and place,” American Journal of Epidemiology, vol. 168, no. 10, pp. 1099–1109, 2008.
[53]  H. Hagan, H. Thiede, and D. C. Des Jarlais, “HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention,” AIDS, vol. 19, supplement 3, pp. S199–S207, 2005.
[54]  R. M. Klevens, D. J. Hu, R. Jiles, and S. D. Holmberg, “Evolving epidemiology of hepatitis C virus in the United States,” Clinical Infectious Diseases, vol. 55, supplement 1, pp. S3–S9, 2012.
[55]  K. N. Ly, J. Xing, R. M. Klevens, R. B. Jiles, J. W. Ward, and S. D. Holmberg, “The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007,” Annals of Internal Medicine, vol. 156, no. 4, pp. 271–278, 2012.
[56]  Global Commission on Drug Policy, The War on Drugs and HIV/AIDS: How the Criminalization of Drug Use Fuels the Global Pandemic, edited by Policy GCoD, 2012.
[57]  D. C. Des Jarlais, K. Arasteh, C. McKnight, H. Hagan, D. C. Perlman, and S. Semaan, “Associations between herpes simplex virus type 2 and HCV with HIV among injecting drug users in New York City: the current importance of sexual transmission of HIV,” American Journal of Public Health, vol. 101, no. 7, pp. 1277–1283, 2011.
[58]  A. H. Kral, J. Lorvick, D. Ciccarone et al., “HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco,” Journal of Urban Health, vol. 82, no. 1, supplement, pp. i43–i50, 2005.
[59]  S. A. Strathdee and J. K. Stockman, “Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions,” Current HIV/AIDS Reports, vol. 7, no. 2, pp. 99–106, 2010.
[60]  N. Meader, R. Li, D. C. Des Jarlais, and S. Pilling, “Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users (Review),” Cochrane Database of Systematic Reviews, no. 1, article CD007192, 2010.
[61]  J. Cohen, “HIV treatment as prevention,” Science, vol. 334, no. 6063, p. 1628, 2011.
[62]  M. S. Cohen, Y. Q. Chen, M. McCauley et al., “Prevention of HIV-1 infection with early antiretroviral therapy,” The New England Journal of Medicine, vol. 365, no. 6, pp. 493–505, 2011.
[63]  Z. Jia, Y. Ruan, Q. Li et al., “Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003–2011): a national observational cohort study,” The Lancet, vol. 6736, no. 12, pp. 61898–61904, 2012.
[64]  United States Department of State, Remarks at the 2012 International AIDS Conference: Hillary Rodham Clinton, AIDS, Washington, DC, USA, 2012.
[65]  D. Musto, The American Disease: Origins of Narcotic Control, Yale University Press, New Haven, CT, USA, 1973.
[66]  D. R. Davis, African Americans and Cocaine: A Historiography, Michigan State University, 2008.
[67]  C. G. Vélez-Ibá?ez, Border Visions: Mexican Cultures of the Southwest United States, University of ARIZONA Press, Tucson, Ariz, USA, 1996.
[68]  D. Hiro, Inside Central Asia: A Political and Cultural History of Uzbekistan, Turkmenistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkey, and Iran, Overlook, New York, NY, USA, 2009.
[69]  Division of Criminal Justice Services, 2009 Drug Law Changes, June 2012 Update, Performance OoJRa, Albany, GA, USA.
[70]  D. F. Musto, “Opium, cocaine and marijuana in American history,” Scientific American, vol. 265, no. 1, pp. 40–47, 1991.
[71]  G. A. Marlatt, M. E. Larimer, and K. A. Witkiewitz, Harm Reduction: Pragmatic Strategies For Managing High-Risk Behaviors, Guilford Publications, New York, NY, USA, 2nd edition, 2011.
[72]  R. Pates and D. Riley, Harm Reduction in Substance Use and High-Risk Behaviour, Wiley, Chichester, UK, 2012.
[73]  L. Johnston, M. O’Malley, J. Bachman, and J. Schulenberg, Monitoring the Future: National Results on Adolescent Drug Use, The University of Michigan Institute for Social Research, Ann Arbor, Mich, USA, 2011.
[74]  United Nations Office on Drugs Crime, Rise in Methamphetamine Abuse Among Youth in SE Asia: Shortage of Qualified Drug Treatment Professionals Hampers Drug Treatment Services, Southeast Asia and Pacific Reports, Crime UNOoDa, Bangkok, Thailand, 2012.
[75]  E. Wood, D. Werb, M. Kazatchkine et al., “Vienna declaration: a call for evidence-based drug policies,” The Lancet, vol. 376, no. 9738, pp. 310–312, 2010.
[76]  A. E. Yamin, “The right to health under international law and its relevance to the United States,” American Journal of Public Health, vol. 95, no. 7, pp. 1156–1161, 2005.
[77]  World Health Organization, Assessment of Compulsory Treatment of People Who Use Drugs in Cambodia, China, Malaysia and Viet Nam: An Application of Selected Human Rights Principles, WHO, Geneva, Switzerland, 2009.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133